The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.
Cancer treatment therapies: traditional to modern approaches to combat cancers
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“More effective results may be obtained by combining liposomal anthracycline with a monoclonal antibody against HER2/neu [115, 116].”
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Photodynamic therapy of cancer: An update
Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., Hahn, S. M., Hamblin, M. R., Juzeniene, A., Kessel, D., et al. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20114 · Cited by 5,145 · cited 1×
“The latest studies suggest that PDT may be an effective postoperative treatment, enhancing the likelihood of maintaining local disease control in the long term [30].”
BackgroundBatlle, E., & Clevers, H. (2017) · Nature Medicine · doi:10.1038/nm.4409 · Cited by 2,769
Combination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543
Hematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522
Wu, X., Liu, H., Liu, J., Haley, K. N., Treadway, J. A., Larson, J. P., Ge, N., Peale, F., & Bruchez, M. P. (2003) · Nature Biotechnology · doi:10.1038/nbt764 · Cited by 2,506
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,663
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
Barua, S., & Mitragotri, S. (2014) · Nano Today · doi:10.1016/j.nantod.2014.04.008 · Cited by 1,257
The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.
Freeman, S. M., Abboud, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D. S., Moolten, F. L., & Abraham, G. N. (1993) · PubMed · Cited by 1,084
Ganesh, K., & Massagué, J. (2021) · Nature Medicine · doi:10.1038/s41591-020-01195-4 · Cited by 1,051
Hua, S., de Matos, M. B. C., Metselaar, J. M., & Storm, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00790 · Cited by 1,048
Bagalkot, V., Zhang, L., Levy-Nissenbaum, E., Jon, S., Kantoff, P. W., Langer, R., & Farokhzad, O. C. (2007) · Nano Letters · doi:10.1021/nl071546n · Cited by 1,036
Solid lipid nanoparticles: A modern formulation approach in drug delivery system
Mukherjee, S., Ray, S., & Thakur, R. (2009) · Indian Journal of Pharmaceutical Sciences · doi:10.4103/0250-474x.57282 · Cited by 1,000
Assessment of the Evolution of Cancer Treatment Therapies
Arruebo, M., Vilaboa, N., Sáez-Gutierrez, B., Lambea, J., Tres, A., Valladares, M., & González-Fernández, Á. (2011) · Cancers · doi:10.3390/cancers3033279 · Cited by 931
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
Innovative approaches for cancer treatment: current perspectives and new challenges
Pucci, C., Martinelli, C., & Ciofani, G. (2019) · ecancermedicalscience · doi:10.3332/ecancer.2019.961 · Cited by 814
Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases
Gabathuler, R. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.028 · Cited by 802
Cancer active targeting by nanoparticles: a comprehensive review of literature
Bazak, R., Houri, M., El Achy, S., Kamel, S., & Refaat, T. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1767-3 · Cited by 756
Tumor-Derived Exosomes and Their Role in Cancer Progression
(2016) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2015.12.005 · Cited by 755
Urban-Klein, B., Werth, S., Abuharbeid, S., Czubayko, F., & Aigner, A. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302425 · Cited by 716
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
Biological functions of mesenchymal stem cells and clinical implications
Naji, A., Eitoku, M., Favier, B., Deschaseaux, F., Rouas-Freiss, N., & Suganuma, N. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03125-1 · Cited by 624
Ulbrich, K., Hekmatara, T., Herbert, E., & Kreuter, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.08.021 · Cited by 591
Oxidative stress and dietary phytochemicals: Role in cancer chemoprevention and treatment
Chikara, S., Nagaprashantha, L. D., Singhal, J., Horne, D., Awasthi, S., & Singhal, S. S. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.002 · Cited by 559
Demeule, M., Currie, J., Bertrand, Y., Ché, C., Nguyen, T., Régina, A., Gabathuler, R., Castaigne, J., & Béliveau, R. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05492.x · Cited by 557
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Ye, F., Dewanjee, S., Li, Y., Jha, N. K., Chen, Z.-S., Kumar, A., Vishakha, Behl, T., Jha, S. K., & Tang, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01805-y · Cited by 554
Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance
Shapira, A., Livney, Y. D., Broxterman, H. J., & Assaraf, Y. G. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.003 · Cited by 504
Park, J. Y., Baek, M. J., Choi, E. S., Woo, S., Kim, J. H., Kim, T. J., Jung, J. C., Chae, K. S., Chang, Y., & Lee, G. H. (2009) · ACS Nano · doi:10.1021/nn900761s · Cited by 504
Targeting receptor-mediated endocytotic pathways with nanoparticles: Rationale and advances
Xu, S., Olenyuk, B. Z., Okamoto, C. T., & Hamm-Alvarez, S. F. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.041 · Cited by 467
Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance
Chang, J. C. (2016) · Medicine · doi:10.1097/md.0000000000004766 · Cited by 435
Muhamad, N., Plengsuriyakarn, T., & Na-Bangchang, K. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s165210 · Cited by 410
Correlated light and electron microscopic imaging of multiple endogenous proteins using Quantum dots
Giepmans, B. N. G., Deerinck, T. J., Smarr, B. L., Jones, Y. Z., & Ellisman, M. H. (2005) · Nature Methods · doi:10.1038/nmeth791 · Cited by 388
Functional precision cancer medicine—moving beyond pure genomics
Letai, A. (2017) · Nature Medicine · doi:10.1038/nm.4389 · Cited by 366
Natural products for human health: an historical overview of the drug discovery approaches
Bernardini, S., Tiezzi, A., Laghezza Masci, V., & Ovidi, E. (2018) · Natural Product Research · doi:10.1080/14786419.2017.1356838 · Cited by 355
Nucleic Acid Aptamers: Clinical Applications and Promising New Horizons
Ni, X., Castanares, M., Mukherjee, A., & Lupold, S. E. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797189600 · Cited by 349
Advancing the field of drug delivery
Moses, M. A., Brem, H., & Langer, R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00276-9 · Cited by 343
siRNA Conjugate Delivery Systems
Jeong, J. H., Mok, H., Oh, Y.-K., & Park, T. G. (2009) · Bioconjugate Chemistry · doi:10.1021/bc800278e · Cited by 338
The role of photodynamic therapy in overcoming cancer drug resistance
Spring, B. Q., Rizvi, I., Xu, N., & Hasan, T. (2015) · Photochemical & Photobiological Sciences · doi:10.1039/c4pp00495g · Cited by 335
Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy
Acharya, S., Dilnawaz, F., & Sahoo, S. K. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.07.008 · Cited by 333
Shenoy, D. B., & Amiji, M. M. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.12.010 · Cited by 331
Extracellular Vesicles in Cancer Immune Microenvironment and Cancer Immunotherapy
Xie, F., Zhou, X., Fang, M., Li, H., Su, P., Tu, Y., Zhang, L., & Zhou, F. (2019) · Advanced Science · doi:10.1002/advs.201901779 · Cited by 327
Cytokines in immunogenic cell death: Applications for cancer immunotherapy
Showalter, A., Limaye, A., Oyer, J. L., Igarashi, R., Kittipatarin, C., Copik, A. J., & Khaled, A. R. (2017) · Cytokine · doi:10.1016/j.cyto.2017.05.024 · Cited by 319
FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels
Trujillo-Alonso, V., Pratt, E. C., Zong, H., Lara-Martinez, A., Kaittanis, C., Rabie, M. O., Longo, V., Becker, M. W., Roboz, G. J., Grimm, J., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0406-1 · Cited by 319
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
Dai, H., Wang, Y., Lu, X., & Han, W. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv439 · Cited by 299
Garg, A. D., Krysko, D. V., Vandenabeele, P., & Agostinis, P. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1184-2 · Cited by 292
Mesenchymal stem cell exosomes: a two-edged sword in cancer therapy
Vakhshiteh, F., Atyabi, F., & Ostad, S. N. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s200036 · Cited by 281
Engineered neutrophil-derived exosome-like vesicles for targeted cancer therapy
Zhang, J., Ji, C., Zhang, H., Shi, H., Mao, F., Qian, H., Xu, W., Wang, D., Pan, J., Fang, X., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj8207 · Cited by 265
Henderson, B. W., Gollnick, S. O., Snyder, J. W., Busch, T. M., Kousis, P. C., Cheney, R. T., & Morgan, J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3513 · Cited by 263
Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates
Sharkey, R. M., & Goldenberg, D. M. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.4.226 · Cited by 242
Nanostructured carriers as innovative tools for cancer diagnosis and therapy
Martinelli, C., Pucci, C., & Ciofani, G. (2019) · APL Bioengineering · doi:10.1063/1.5079943 · Cited by 228
RNA Interference-Induced Innate Immunity, Off-Target Effect, or Immune Adjuvant?
Meng, Z., & Lu, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00331 · Cited by 224
p53 Mutations and Survival in Stage I Non-Small-Cell Lung Cancer: Results of a Prospective Study
Ahrendt, S. A., Hu, Y., Buta, M., McDermott, M. P., Benoit, N., Yang, S. C., Wu, L., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.13.961 · Cited by 222
Chu, D.-T., Nguyen, T. T., Tien, N. L. B., Tran, D.-K., Jeong, J.-H., Anh, P. G., Thanh, V. V., Truong, D. T., & Dinh, T. C. (2020) · Cells · doi:10.3390/cells9030563 · Cited by 216
A Review of Chemotherapy and Photodynamic Therapy for Lung Cancer Treatment
El‐Hussein, A., Manoto, S. L., Ombinda-Lemboumba, S. S., Alrowaili, Z. A., & Mthunzi-Kufa, P. T. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200403144945 · Cited by 210
Recht, L., Torres, C. O., Smith, T. W., Raso, V., & Griffin, T. W. (1990) · Journal of Neurosurgery · doi:10.3171/jns.1990.72.6.0941 · Cited by 185
Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice
Gu, X., Erb, U., Büchler, M. W., & Zöller, M. (2015) · International Journal of Cancer · doi:10.1002/ijc.29100 · Cited by 185
Fleming, J. B., Shen, G.-L., Holloway, S. E., Davis, M., & Brekken, R. A. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-04-0206 · Cited by 176 · cited 1×
“This technique depends on siRNA-mediated gene suppression of antiapoptotic proteins, transcription factors (such as the c-myc gene), or cancer-related genes (such as the K-RAS gene) [61].”
Mesenchymal Stem Cells and Cancer: Clinical Challenges and Opportunities
Lin, W., Huang, L., Li, Y., Fang, B., Li, G., Chen, L., & Xu, L. (2019) · BioMed Research International · doi:10.1155/2019/2820853 · Cited by 165
Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy
Naseri, M., Bozorgmehr, M., Zöller, M., Pirmardan, E. R., & Madjd, Z. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1779991 · Cited by 163
siRNA based drug design, quality, delivery and clinical translation
Subhan, M. A., & Torchilin, V. P. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102239 · Cited by 154
Molecular Tumor Boards: current practice and future needs
Velden, D. L. V. D., van Herpen, C. M. L., van Laarhoven, H. W. M., Smit, E. F., Groen, H. J. M., Willems, S. M., Nederlof, P. M., Langenberg, M. H. G., Cuppen, E. P. J. G., Sleijfer, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx528 · Cited by 147
Nanoparticles for Imaging and Treating Brain Cancer
Meyers, J. D., Doane, T. L., Burda, C., & Basilion, J. P. (2012) · Nanomedicine · doi:10.2217/nnm.12.185 · Cited by 146
Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
Wagner, M. J., Mitra, R., McArthur, M. J., Baze, W. B., Barnhart, K. F., Wu, S. Y., Rodriguez‐Aguayo, C., Zhang, X., Coleman, R. L., Lopez‐Berestein, G., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0541 · Cited by 137
Panzarini, E., Inguscio, V., Fimia, G. M., & Dini, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105778 · Cited by 132
Wang, G., Hu, W., Chen, H., Shou, X., Ye, T., & Xu, Y. (2019) · Cancers · doi:10.3390/cancers11101560 · Cited by 132
Oxidative Stress in Cancer Therapy: Friend or Enemy?
Azmanova, M., & Pitto‐Barry, A. (2022) · ChemBioChem · doi:10.1002/cbic.202100641 · Cited by 131
Effects of quercetin on proliferation and migration of human glioblastoma U251 cells
Liu, Y., Tang, Z., Lin, Y., Qu, X., Lv, W., Wang, G., & Li, C.-L. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.044 · Cited by 130
Remsen, L. G., McCormick, C. I., Roman-Goldstein, S., Nilaver, G., Weissleder, R., Bogdanov, A. A., Jr., Hellström, K. E., Kroll, R. A., & Neuwelt, E. A. (1996) · PubMed Central · Cited by 123
Genetically modified mesenchymal stromal cells in cancer therapy
Sage, E. K., Thakrar, R. M., & Janes, S. M. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.09.003 · Cited by 122
Mahaweni, N. M., Kaijen-Lambers, M. E. H., Dekkers, J., Aerts, J. G. J. V., & Hegmans, J. P. (2013) · Journal of Extracellular Vesicles · doi:10.3402/jev.v2i0.22492 · Cited by 119
Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications
Räty, J. K., Pikkarainen, J. T., Wirth, T. C., & Ylä‐Herttuala, S. (2008) · Current Molecular Pharmacology · doi:10.2174/1874467210801010013 · Cited by 118
Ultra‐small gadolinium oxide nanoparticles to image brain cancer cells in vivo with MRI
Faucher, L., Guay‐Bégin, A., Lagueux, J., Côté, M., Petitclerc, É., & Fortin, M. (2010) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.420 · Cited by 114
Shams, M., Owczarczak, B., Manderscheid, P. A., Bellnier, D. A., & Gollnick, S. O. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1633-9 · Cited by 114
Antisense RNA gene therapy for studying and modulating biological processes
Weiss, B., Davidkova, G., & Zhou, L.-W. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050296 · Cited by 113
Harnessing the exosome-induced immune response for cancer immunotherapy
Gehrmann, U., Näslund, T. I., Hiltbrunner, S., Larssen, P., & Gabrielsson, S. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.05.003 · Cited by 111
An Exosome‐Based Vaccine Platform Imparts Cytotoxic T Lymphocyte Immunity Against Viral Antigens
Anticoli, S., Manfredi, F., Chiozzini, C., Arenaccio, C., Olivetta, E., Ferrantelli, F., Capocefalo, A., Falcone, E., Ruggieri, A., & Federico, M. (2017) · Biotechnology Journal · doi:10.1002/biot.201700443 · Cited by 107
Delivery of Nanoparticles for Treatment of Brain Tumor
Chen, K., Sun, Y., Zhu, J., Li, W., Zhang, A., Kuang, T., Xie, J., & Yang, Z. (2016) · Current Drug Metabolism · doi:10.2174/1389200217666160728152939 · Cited by 103
Yang, F., SONG, L., Wang, H., Wang, J., Xu, Q., & Xing, N. (2015) · Oncology Reports · doi:10.3892/or.2015.3886 · Cited by 101
Cucurmin, anticancer, & antitumor perspectives: A comprehensive review
Imran, M., Ullah, A., Saeed, F., Nadeem, M., Arshad, M. U., & Suleria, H. A. R. (2016) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2016.1252711 · Cited by 101
Poloxamine-based nanomaterials for drug delivery
Alvarez‐Lorenzo, C. (2010) · Frontiers in Bioscience-Elite · doi:10.2741/e102 · Cited by 99
Exosomes from Plasmacytoma Cells as a Tumor Vaccine
Altieri, S. L., Khan, A. N. H., & Tomasi, T. B. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200407000-00004 · Cited by 99
Casper, J., Wolff, D., Knauf, W. U., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3429 · Cited by 95
Xiao, L., Erb, U., Zhao, K., Hackert, T., & Zöller, M. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1319044 · Cited by 94
Montazerabadi, A., Sazgarnia, A., Bahreyni-Toosi, M. H., Ahmadi, A., & Aledavood, A. (2012) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2012.01.004 · Cited by 93
Natural polyphenols: a promising bioactive compounds for skin care and cosmetics
Bharadvaja, N., Gautam, S., & Singh, H. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-08156-9 · Cited by 92
Introduction of theCIITAgene into tumor cells produces exosomes with enhanced anti-tumor effects
Lee, Y. S., Kim, S. H., Cho, J. A., & Kim, C. W. (2011) · Experimental & Molecular Medicine · doi:10.3858/emm.2011.43.5.029 · Cited by 91
CRISPR/Cas9 system in breast cancer therapy: advancement, limitations and future scope
Karn, V., Sandhya, S., Hsu, W., Parashar, D., Singh, H. N., Jha, N. K., Gupta, S. K., Dubey, N. K., & Kumar, S. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02654-3 · Cited by 88
Self-citationSullivan, C., Porter, R. M., Evans, C. H., Ritter, T., Shaw, G., Barry, F., & Murphy, J. M. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt492 · Cited by 87
Tanaka, M., Kataoka, H., Yano, S., Sawada, T., Akashi, H., Inoue, M., Suzuki, S., Inagaki, Y., Hayashi, N., Nishie, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9725 · Cited by 84
Rapid Advances in Immunotherapy to Treat Cancer
McCune, J. S. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.985 · Cited by 84
Therapeutic Nanoparticles for Targeted Delivery of Anticancer Drugs
Alasvand, N., Urbanska, A. M., Rahmati, M., Saeidifar, M., Gungor‐Ozkerim, P. S., Sefat, F., Rajadas, J., & Mozafari, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-52725-5.00013-7 · Cited by 83
Exosome-mediated microenvironment dysregulation in leukemia
Kumar, B., García, M., Murakami, J. L., & Chen, C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.09.017 · Cited by 82
Peptide conjugated polymeric nanoparticles as a carrier for targeted delivery of docetaxel
Kulhari, H., Pooja, D., Shrivastava, S., Naidu, V. G. M., & Sistla, R. (2014) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2014.02.026 · Cited by 78
Okada, S., Vaeteewoottacharn, K., & Kariya, R. (2018) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c17-00789 · Cited by 78
Personalized medicine and back–allogeneic exosomes for cancer immunotherapy
Samuel, M., & Gabrielsson, S. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12963 · Cited by 76
Ruiss, R., Jochum, S., Mocikat, R., Hammerschmidt, W., & Zeidler, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025294 · Cited by 73
Lamberti, M. J., Vittar, N. B. R., & Rivarola, V. A. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i5.901 · Cited by 68
Farooqi, A. A., Qureshi, M. Z., Khalid, S., Attar, R., Martinelli, C., Sabitaliyevich, U. Y., Nurmurzayevich, S. B., Taverna, S., Poltronieri, P., & Xu, B. (2019) · Cancers · doi:10.3390/cancers11040478 · Cited by 68
Patient-derived xenograft models—the future of personalised cancer treatment
Bhimani, J., Ball, K., & Stebbing, J. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0678-0 · Cited by 64
Mobilization and collection of peripheral blood progenitor cells for transplantation
Reddy, R. L. (2005) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2004.10.007 · Cited by 63
Garg, A. D., Maes, H., Romano, E., & Agostinis, P. (2015) · Photochemical & Photobiological Sciences · doi:10.1039/c4pp00466c · Cited by 62
Kim, H. S., Song, I. H., Kim, J. C., et al. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.08.003 · Cited by 62
Exosome plays an important role in the development of hepatocellular carcinoma
Li, L., Liu, Z.-X., & Cheng, Q. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152468 · Cited by 59
Andreozzi, P., Diamanti, E., Py-Daniel, K. R., Cáceres‐Vélez, P. R., Martinelli, C., Πολιτάκος, Ν., Escobar, A., Muzi-Falconi, M., Azevedo, R. B., & Moya, S. E. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b11132 · Cited by 53
Photodynamic therapy for enhancing antitumour immunity
Pížová, K., Tomankova, K. B., Daskova, A., Binder, S., Bajgar, R., & Kolářová, H. (2012) · Biomedical Papers · doi:10.5507/bp.2012.056 · Cited by 52
Dendritic cell-derived exosomes: A new horizon in personalized cancer immunotherapy?
Ghorbaninezhad, F., Alemohammad, H., Najafzadeh, B., Masoumi, J., Shadbad, M. A., Shahpouri, M., Saeedi, H., Rahbarfarzam, O., & Baradaran, B. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216168 · Cited by 50
Abballe, L., Spinello, Z., Antonacci, C., Coppola, L., Miele, E., Catanzaro, G., & Miele, E. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020505 · Cited by 45
Li, R., Chibbar, R., & Xiang, J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s184898 · Cited by 40
Advancing molecular tumour boards: highly needed to maximise the impact of precision medicine
van de Haar, J., Hoes, L. R., & Voest, E. E. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000516 · Cited by 40
Recent advances in siRNA delivery
Sarısözen, C., Salzano, G., & Torchilin, V. P. (2015) · BioMolecular Concepts · doi:10.1515/bmc-2015-0019 · Cited by 38
Emerging Roles and Potential Applications of Non-Coding RNAs in Cervical Cancer
Parashar, D., Singh, A. K., Gupta, S. K., Sharma, A., Sharma, M. K., Roy, K. K., Chauhan, S. C., & Kashyap, V. K. (2022) · Genes · doi:10.3390/genes13071254 · Cited by 37
Self-citationXie, Y., Wang, L., Freywald, A., Qureshi, M., Chen, Y., & Xiang, J. (2012) · Cellular and Molecular Immunology · doi:10.1038/cmi.2012.37 · Cited by 36
The Implications and Future Perspectives of Nanomedicine for Cancer Stem Cell Targeted Therapies
Singh, V. K., Saini, A., & Chandra, R. (2017) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2017.00052 · Cited by 31
Beyond Macromolecules: Extracellular Vesicles as Regulators of Inflammatory Diseases
Das, K., Paul, S., Mukherjee, T., Ghosh, A., Sharma, A., Shankar, P., Gupta, S. K., Keshava, S., & Parashar, D. (2023) · Cells · doi:10.3390/cells12151963 · Cited by 31
Self-citationHow can nanotechnology help membrane vesicle-based cancer immunotherapy development?
Tian, X., Zhu, M., & Nie, G. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.22130 · Cited by 29
Purinergic signalling in cancer therapeutic resistance: From mechanisms to targeting strategies
Jia, W., Huang, Z., Zhou, L., Liou, Y., Virgilio, F. D., Ulrich, H., Illés, P., Zhang, W., Huang, C., & Tang, Y. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100988 · Cited by 28
Reprogramming Exosomes for Immunotherapy
Cheng, Q., Shi, X., & Zhang, Y. (2019) · Methods in molecular biology · doi:10.1007/978-1-0716-0203-4_12 · Cited by 27
Lo, V. C. K., Akens, M. K., Moore, S., Yee, A., Wilson, B. C., & Whyne, C. M. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2146-x · Cited by 26
Javid, S., Ziamajidi, N., Foroughi, S., & Abbasalipourkabir, R. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.12.055 · Cited by 22
Is the exosome a potential target for cancer immunotherapy?
Yoshimura, A., Sawada, K., & Kimura, T. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.01.47 · Cited by 16
Potentiating antitumor immunity with αGC-loaded exosomes
Gehrmann, U., Hiltbrunner, S., Näslund, T. I., & Gabrielsson, S. (2013) · OncoImmunology · doi:10.4161/onci.26261 · Cited by 15
Cited by
El-khawaga, A. M., Youssef, O. I., El-dydamoni, O. A., Ragab, W. M., & Mohammed, R. A. E. (2026) · European Journal of Medical Research · doi:10.1186/s40001-025-03804-9 · Cited by 14
Current Status of Research on Losartan in Tumour Therapy
Wang, H., Yuan, S., & Wang, H. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70985 · Cited by 11
“such as drug resistance, tumour recurrence and distant metastasis often result in unsatisfactory long-term outcomes for many patients [6].”
Wang, Y., Han, X., Zhang, S., Wang, L., Sun, S., Xue, C., & Yao, T. (2025) · Biopolymers · doi:10.1002/bip.70054 · Cited by 6
Metadata
- Authors
- Kaur, R., Bhardwaj, A., & Gupta, S.
- Venue
- Molecular Biology Reports
- Published
- 2023-10-12
- Volume
- 50
- Issue
- 11
- Pages
- 9663-9676
- ISSN
- 0301-4851 (ISSN-L)
- 1573-4978
- OpenAlex
- W4387580807
- Cited by
- 561
- References
- 129
- FWCI
- 41.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.